Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05637216 · ClinicalTrials.gov registry record · Phase 2
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
A Phase 2 study of Radiation Induced Fibrosis, sponsored by Shaw Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05637216 is a Phase 2 study of Radiation Induced Fibrosis that is actively recruiting participants, run by Shaw Cancer Center. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05637216, a Phase 2 study of Radiation Induced Fibrosis, is actively recruiting participants, sponsored by Shaw Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the efficacy of losartan (LOS), an FDA-approved transforming growth factor beta-1 (TGF-β1) blocker, to decrease radiation induced fibrosis (RIF) in the breast and the lung of breast cancer patients, testing the hypothesis that Losartan will decrease RIF, TGF- β1 and cellular senescence/inflammation in the breast and the lung of irradiated breast cancer patients relative to placebo treatment and consequently improve clinical outcomes in breast cancer patients.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Losartan 25 milligram capsule
Study Locations (1)
Colorado
- Vail Health Shaw Cancer Center - Edwards
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-17 |
| Est. Completion | 2027-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05637216
The ClinicalTrials.gov registry entry for NCT05637216 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shaw Cancer Center, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Radiation Induced Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05637216 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT05637216 about?
NCT05637216 is a clinical study titled "Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients". This study will evaluate the efficacy of losartan (LOS), an FDA-approved transforming growth factor beta-1 (TGF-β1) blocker, to decrease radiation induced fibrosis (RIF) in the breast and the lung of breast cancer patients, testing the hypothesis that Losartan will decrease RIF, TGF- β1 and cellular...
What is the current status of trial NCT05637216?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2023-08-17. Estimated completion is 2027-08-17.
What conditions does trial NCT05637216 study?
This clinical trial studies the following conditions: Radiation Induced Fibrosis.
What interventions are being tested in trial NCT05637216?
The interventions under investigation include: Placebo (DRUG), Losartan 25 milligram capsule (DRUG).
Who is sponsoring clinical trial NCT05637216?
This trial is sponsored by Shaw Cancer Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05637216 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.